Prediction of therapeutic efficacy for intestinal inflammation by microbiome

Prediction of therapeutic efficacy for inflammatory bowel disease by intestinal microbiome - Therapeutic efficacy for IBD by intestinal microbiome

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031240594

Enrollment

400

Registered

2025-01-06

Start date

2021-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease, IBD,UC,CD,

Interventions

collecting stool sumples

Sampling

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Ulcerative colitis and Crohn's disease diganosed by clinical, radiological, endoscopical, and pathological findings. 2) Clinically required to start biological agents. 3) Obtained written concent.

Exclusion criteria

Exclusion criteria: 1) Individuals who stopped threatment due to adverse events or unexpected reactions. 2) Individuals who were started corticosteroid treatment within 16 weeks of biologics induction. 3) Individuals who were taking antibiotics at the time of stool sumpling.

Design outcomes

Primary

Measure	Time frame
intestinal microbiome	—

Contacts

Public ContactMasayuki Fukata

Tokyo Ymate Medical Center

fukata-masayuki@yamate.jcho.go.jp+81-3-3364-0251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026